Sanofi SA (SNY) Appoints New R&D Head Amid 5% Dividend Yield

Sanofi SA (NASDAQ: SNY) announced the appointment of Paulo Fontoura as Executive Vice President and Global Head of Research & Development effective September 1. Fontoura will oversee the company's end-to-end innovation engine across multiple therapeutic areas, succeeding Dr. Houman Ashrafian. The appointment is significant as Sanofi progresses in its R&D transformation and aims to accelerate the development of new medicines. Additionally, MacroGenics confirmed it will receive $24.5 million from Sanofi due to regulatory milestone payments related to the FDA's accelerated approval of TZIELD.